NASDAQ:COEP Coeptis Therapeutics (COEP) Stock Price, News & Analysis $17.50 +0.84 (+5.04%) Closing price 04:00 PM EasternExtended Trading$17.08 -0.43 (-2.43%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About Coeptis Therapeutics Stock (NASDAQ:COEP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Coeptis Therapeutics alerts:Sign Up Key Stats Today's Range$16.33▼$17.8450-Day Range$10.60▼$17.8552-Week Range$2.31▼$19.19Volume35,365 shsAverage Volume59,283 shsMarket Capitalization$84.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania. Read More Coeptis Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks9th Percentile Overall ScoreCOEP MarketRank™: Coeptis Therapeutics scored higher than 9% of companies evaluated by MarketBeat, and ranked 925th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Coeptis Therapeutics. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Coeptis Therapeutics is -3.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Coeptis Therapeutics is -3.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCoeptis Therapeutics has a P/B Ratio of 10.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.54% of the float of Coeptis Therapeutics has been sold short.Short Interest Ratio / Days to CoverCoeptis Therapeutics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Coeptis Therapeutics has recently increased by 8.89%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCoeptis Therapeutics does not currently pay a dividend.Dividend GrowthCoeptis Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.54% of the float of Coeptis Therapeutics has been sold short.Short Interest Ratio / Days to CoverCoeptis Therapeutics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Coeptis Therapeutics has recently increased by 8.89%, indicating that investor sentiment is decreasing significantly. News and Social Media2.2 / 5News Sentiment0.95 News SentimentCoeptis Therapeutics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Coeptis Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for COEP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Coeptis Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders24.25% of the stock of Coeptis Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.88% of the stock of Coeptis Therapeutics is held by institutions.Read more about Coeptis Therapeutics' insider trading history. Receive COEP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coeptis Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. COEP Stock News HeadlinesVanderbilt Report: Coeptis Shows How Biotech Can Fund Itself While InnovatingSeptember 23 at 8:00 AM | globenewswire.comCoeptis Therapeutics Holdings, Inc. Announces Extinguishment of Convertible Note, Strengthening Capital StructureJuly 22, 2025 | quiverquant.comQForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He says a 4-nanometer device that's 80 MILLION times more powerful than the chip he gave Reagan is now being made in America for the first time. And he's identified 3 companies that control this technology.September 26 at 2:00 AM | Banyan Hill Publishing (Ad)Coeptis (COEP) Extinguishes Convertible Note with YA II PN, LtdJuly 22, 2025 | globenewswire.comCoeptis Therapeutics Holdings, Inc. (COEPW) - Yahoo FinanceJuly 8, 2025 | finance.yahoo.comCoeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared - MorningstarJune 27, 2025 | morningstar.comMCoeptis Therapeutics Files Form S-4 Registration Statement for Proposed Merger with Z Squared Inc. - NasdaqJune 27, 2025 | nasdaq.comCoeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z SquaredJune 26, 2025 | globenewswire.comSee More Headlines COEP Stock Analysis - Frequently Asked Questions How have COEP shares performed this year? Coeptis Therapeutics' stock was trading at $5.50 at the beginning of the year. Since then, COEP shares have increased by 218.2% and is now trading at $17.50. How were Coeptis Therapeutics' earnings last quarter? Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) posted its earnings results on Thursday, August, 14th. The company reported ($1.17) earnings per share (EPS) for the quarter. The firm had revenue of $0.20 million for the quarter. When did Coeptis Therapeutics' stock split? Coeptis Therapeutics's stock reverse split before market open on Tuesday, December 31st 2024.The 1-20 reverse split was announced on Friday, December 27th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, December 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Coeptis Therapeutics? Shares of COEP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Coeptis Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Coeptis Therapeutics investors own include Avino Silver & Gold Mines (ASM), PayPal (PYPL), Tesla (TSLA), Meta Platforms (META), 3M (MMM), PHX Minerals (PHX) and P3 Health Partners (PIII). Company Calendar Last Earnings8/14/2025Today9/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:COEP CIK1759186 Webcoeptispharma.com Phone724-934-6467FaxN/AEmployees2Year FoundedN/AProfitability EPS (Trailing Twelve Months)($5.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.88 million Net MarginsN/A Pretax Margin-4,771.59% Return on Equity-201.73% Return on Assets-108.46% Debt Debt-to-Equity Ratio0.02 Current Ratio0.83 Quick Ratio0.83 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.61 per share Price / Book10.87Miscellaneous Outstanding Shares4,820,000Free Float3,651,000Market Cap$84.35 million OptionableNot Optionable Beta-0.57 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:COEP) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coeptis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.